100% CR rate (6 of 6 patients), with 40% CR rate (2 of 5 patients) at 6 months, achieved as best response following 1 dose at the initial dose level in patients with aggressive r/r B-NHL --
-- First patient treated in the ANTLER trial remained in CR at 12 months --
-- Based on promising initial safety profile and clinical activity, ANTLER Phase 1 trial enrolling patients at dose level 2 --
-- CB-010 is the 1st allogeneic CAR-T cell therapy in the clinic with a PD-1 knockout, a genome-editing strategy designed to improve the persistence of antitumor activity --
-- Caribou webcast conference call planned for today at 8:00 am ET --
-- Additional ANTLER data expected by year-end 2022 --
Webcast Conference Call Today at 8:00 am ET
Caribou will host a webcast conference call today to discuss the data presented at EHA on the initial ANTLER data for CB-010.
The live webcast and conference call at 8:00 am ET, with an accompanying presentation, will be accessible under Events in the Investors section of the company’s website. To participate in the conference call, dial 1-844-862-9351 (domestic) or 1-929-517-0932 (international) and reference conference ID #4657536. The archived audio webcast will be available on Caribou’s website following the call and will be available for 30 days.
https://finance.yahoo.com/news/caribou-biosciences-reports-positive-additional-070000061.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.